Evgen Pharma PLC - Manchester-based clinical stage drug development company - Says early preclinical data shows SFX-01 was "effective" in in vitro models of some blood cancers.
"The study investigated the effect of SFX-01 on cells from tissue donated by patients with juvenile myelomonocytic leukaemia, through the UK Paediatric MDS/JMML study," company says, adding: "The study also showed that SFX-01 significantly impacted cell proliferation and increased cytotoxicity in GDM-1 cells, an acute myelomonocytic leukaemia cell line."
Despite coming from a small sample size, Evgen says it is "encouraged" by the data. It is now assessing the "optimal preclinical and clinical strategy" for a development programme of SFX-01 in blood cancers such as JMML and AML.
Chief Executive Huw Jones says: "The data from Oxford and Queen Mary's shows a very exciting opportunity to extend our oncology pipeline by adding blood cancers to the ongoing metastatic breast cancer and glioblastoma programmes."
Current stock price: 5.39 pence, up 15% Tuesday
Year-to-date change: down 47%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
